Theravance Biopharma (TBPH) Cost of Revenue (2014 - 2018)
Theravance Biopharma (TBPH) posted quarterly Cost of Revenue of $632000.0 for Q4 2018, down 72.52% year-over-year from $2.3 million in Q4 2017, and down 10.35% quarter-over-quarter from $705000.0 in Q3 2018.
Theravance Biopharma (TBPH) Cost of Revenue (2014 - 2018) Analysis & Trends
Theravance Biopharma (TBPH) has reported Cost of Revenue for 5 consecutive years, with $632000.0 the latest figure, recorded in Q4 2018.
- In Q4 2018, Cost of Revenue fell 72.52% year-over-year to $632000.0; the TTM figure through Dec 2018 stood at $3.6 million (down 30.74% YoY), while the FY2018 annual figure was $715000.0, down 88.14% from the prior year.
- Cost of Revenue declined to $632000.0 in Q4 2018 per TBPH's latest filing, from $705000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $3.2 million in Q4 2014 and bottomed at $188000.0 in Q1 2014.
- Historically, Cost of Revenue has averaged $1.0 million across 5 years, with a median of $671500.0 in 2016.
- Annual changes were most pronounced in 2017 — Cost of Revenue surged 196.69% — and 2018, when it sank 72.52%.
- Theravance Biopharma's Cost of Revenue stood at $3.2 million in 2014, then decreased by 0.65% to $3.2 million in 2015, then tumbled by 64.2% to $1.1 million in 2016, then jumped by 100.7% to $2.3 million in 2017, then tumbled by 72.52% to $632000.0 in 2018.
- Business Quant data shows TBPH's Cost of Revenue at $632000.0 in Q4 2018, $705000.0 in Q3 2018, and $1.4 million in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 632,000.00 |
| Dec 31, 2018 | 632,000.00 |
| Sep 30, 2018 | 705,000.00 |
| Sep 30, 2018 | 705,000.00 |
| Jun 30, 2018 | 1.45 Mn |
| Jun 30, 2018 | 1.45 Mn |
| Mar 31, 2018 | 826,000.00 |
| Mar 31, 2018 | 826,000.00 |
| Dec 31, 2017 | 2.30 Mn |
| Dec 31, 2017 | 2.30 Mn |
| Sep 30, 2017 | 985,000.00 |
| Sep 30, 2017 | 985,000.00 |
| Jun 30, 2017 | 1.36 Mn |
| Jun 30, 2017 | 1.36 Mn |
| Mar 31, 2017 | 565,000.00 |
| Mar 31, 2017 | 565,000.00 |
| Dec 31, 2016 | 1.15 Mn |
| Dec 31, 2016 | 1.15 Mn |
| Sep 30, 2016 | 332,000.00 |
| Sep 30, 2016 | 332,000.00 |